

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Lisinopril/HCTZ (Type Z) 10 mg/12.5 mg Tablet (DIN 02301768) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 31, 2021**. The following grouping was removed from the Critical Supply Product List on **April 28, 2021**.

LISINOPRIL/ HYDROCHLOROTHIAZIDE

10 MG / 12.5 MG TABLET

00002362945	LISINOPRIL / HCTZ (TYPE Z)	SNS	\$ 0.2083
00002302365	SANDOZ LISINOPRIL HCT	SDZ	\$ 0.2083
00002301768	TEVA-LISINOPRIL / HCTZ (TYPE Z)	TEV	\$ 0.2083
00002103729	ZESTORETIC	AZC	\$ 0.9286

Removal of temporary benefit from the *ADBL*

Due to the shortage of Xylocaine 2% Topical Jelly (DIN 00001694) manufactured by Aspen Pharmacare Canada Inc, Jelido 2% Topical Jelly (DIN 02469146), manufactured by Pendopharm Inc. was added as a temporary benefit for the *ADBL*.

Aspen Pharmacare Canada Inc has advised Alberta Blue Cross that the shortage of Xylocaine 2% Topical Jelly (DIN 00001694) has been resolved.

As a result, Jelido 2% Topical Jelly (DIN 02469146) will no longer be considered a temporary benefit for the *ADBL* after **May 31, 2021**. The above grouping was removed from the Critical Supply Product List on **April 30, 2021**.

Temporary benefit added to the *ADBL*

Due to the unavailability of Tazorac 0.05% Topical Gel (DIN 02230784) manufactured by Allergan Inc., Tazorac 0.05% Topical Cream (DIN 02243894) will be considered as a temporary benefit for the *ADBL*. The following grouping was added to the Critical Supply Product List on **May 3, 2021**.

As of **May 3, 2021**, all claims for Tazorac 0.05% Topical Cream (DIN 02243894) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

